10 Most Shorted Biotech Stocks to Buy According to Hedge Funds

Page 5 of 10

6. TG Therapeutics Inc. (NASDAQ:TGTX)

TG Therapeutics Inc. (NASDAQ:TGTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds.

On February 26, TG Therapeutics Inc. (NASDAQ:TGTX) reported Q4 revenue of $192.6 million compared with consensus estimates of $193.3 million. In a statement by their CEO, Michael Weiss, 2025 marked a good year for TG Therapeutics, especially with the momentum and organization of BRIUMVI.

The company registered substantial year-over-year growth in the U.S. and globally, driven by increased adoption and availability, while also advancing its late-stage clinical programs and strengthening its financial foundation. As it begins 2026, it continues to build on this foundation with good financial guidance, several key clinical milestones ahead, and a disciplined approach to operating the business, thus enabling it to continue delivering value to patients, healthcare providers, and shareholders.

Back on February 2, a couple of weeks before the earnings results came out, JPMorgan analyst Brian Cheng reduced the firm’s price target on TG Therapeutics Inc. (NASDAQ:TGTX) to $46 from $49. The analyst maintained his Overweight rating on the stock, with a revised upside potential of more than 57%.

TG Therapeutics Inc. (NASDAQ:TGTX) is a commercial-stage biopharmaceutical company dedicated to transforming the treatment landscape for B-cell mediated diseases. They specialize in acquiring, developing, and commercializing innovative therapies, such as BRIUMVI, to help patients manage autoimmune conditions such as multiple sclerosis. By precisely targeting B-cell disorders, they aim to improve patient outcomes and quality of life.

Page 5 of 10